West Pharmaceutical Services makes stoppers. Rubber stoppers. Plungers. Little caps for vials.
CNBC says the stock is more than a GLP-1 play. Congratulations to the rubber stopper. It has range now.
Shares are up around 20% since August, when CNBC first called the valuation attractive. Attractive. Like a casserole at a funeral. Nobody wanted it until someone said it was good.
Now the same people say more upside awaits. Of course they do. Nobody writes "Why we see less upside" after a 20% run. That headline does not exist. That headline gets cancelled by the compliance department.
Here is what the chart says. Number went up. Number may go up again. Number may go down. I charged nothing for this analysis, which is still more than it is worth.
Retail traders will read this and buy the stock. They will tell their spouse it is a "healthcare infrastructure thesis." It is a plug for a vial. Their spouse will nod slowly, the way you nod at a dog that has learned to open the fridge.
They will call it diversification away from GLP-1. They own it because a headline said GLP-1 and then said "not only." That is not research. That is hearing your own name in a crowded room.
The earnings were good. Fine. Earnings are a company describing its own year to strangers. I trust that about as much as a man describing his own fishing trip.
The stopper does not care about your thesis. It sits in the vial and keeps the liquid in.
Which is the one job your portfolio also had.
Photo by on Unsplash
Leave a Comment